Nectar Lifesciences has informed that the meeting of the Board of Directors of the Company is scheduled on 23/01/2026 to consider and approve Unaudited Financial Results for the quarter and nine months ended on December 31, 2025 and matters related thereto and other business matters, if any.
The above information is a part of company’s filings submitted to BSE.